Lv7
4920 积分 2026-03-31 加入
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease
1个月前
已完结
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
Non-invasive tests: Establishing efficacy for metabolic dysfunction–associated steatohepatitis beyond the biopsy—Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration
1个月前
已完结
Transient elastography in acute hospital inpatients with harmful alcohol use: a service evaluation
2个月前
已关闭
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2个月前
已关闭
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
2个月前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
2个月前
已完结
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
2个月前
已关闭
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
2个月前
已完结
Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020
2个月前
已完结
皖公网安备34019202002308
